Tau PET Imaging in Alzheimer’s Disease

Nobuyuki Okamura, Ryuichi Harada, Shozo Furumoto, Hiroyuki Arai, Kazuhiko Yanai, Yukitsuka Kudo

Research output: Contribution to journalReview articlepeer-review

135 Citations (Scopus)


In several neurodegenerative diseases that are collectively called tauopathies, progressive accumulation of tau in the brain is closely associated with neurodegeneration and cognitive impairment. Noninvasive detection of tau protein deposits in the brain would be useful to diagnose tauopathies as well as to track and predict disease progression. Recently, several tau PET tracers including T807, THK-5117, and PBB3 have been developed and succeeded in imaging neurofibrillary pathology in vivo. For use of tau PET as a biomarker of tau pathology in Alzheimer’s disease, PET tracers should have high affinity to PHF-tau and high selectivity for tau over amyloid-β and other protein deposits. PET tau imaging enables the longitudinal assessment of the spatial pattern of tau deposition and its relation to amyloid-β pathology and neurodegeneration. This technology could also be applied to the pharmacological assessment of anti-tau therapy, thereby allowing preventive interventions.

Original languageEnglish
Article number500
JournalCurrent Neurology and Neuroscience Reports
Issue number11
Publication statusPublished - 2014 Nov


  • Amyloid
  • Biomarker
  • Dementia
  • Early diagnosis
  • Neurofibrillary tangles
  • Positron emission tomography
  • Tau


Dive into the research topics of 'Tau PET Imaging in Alzheimer’s Disease'. Together they form a unique fingerprint.

Cite this